Loading
Scynexis Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 02 Apr 2026.
Scynexis Inc: what insiders have been doing
Scynexis Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, the company's managers filed 10 filings, from 8 insiders.
Every open-market trade in the period is a purchase: 1 purchase, from 1 insider, and not a single sale. The amount is not disclosed for 1 filing. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 1 chief executive.
Across the 5,811 companies tracked on its exchange, the median is 19 filings; at 10 filings, this issuer sits below that mark. Looking back to 2021, when coverage begins, insiders filed 4 purchases and no sales.
The clock since the last published purchase (2 April 2026) now reads 199 days. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
55
Thresholds
n/a
Buy Volume
€245,993
4 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleGonzalez David Angulo1 buy
Since the insiders bought
- -39.6%Entry US$7.34 · Close at T+90 US$4.43
- +16.1%Entry US$21.36 · Close at T+365 US$24.80
- +16.1%Entry US$21.36 · Close at T+365 US$24.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Scynexis Inc Strong Buy (bullish), based on 3 analysts. Average price target: US$36.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,397 of 24,148 companies
12.6
score / 100
Value12
Quality14
FCF yld-14%
Earn yld-22%
EV/EBITDA·
ROE-18%
Gross mgn18%
Net mgn-42%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.91
Analyst consensus
3 analystsStrong buy
US$32.00Target US$36.33(+829%)US$44.00
Income statement
RevenueUS$20.6M
Gross profitUS$3.7M18% margin
EBITDA-US$8.4M-41% margin
Net income-US$8.6M-53.3% margin
Valuation
PER (forward)-1.7x
P/Book0.6x
Beta1.06
Balance sheet & cash
Market capUS$38.9M
Total debtUS$2.2M
Free Cash Flow-US$5.3M
Debt / Equity3%
Profitability & ownership
ROE-18.4%
ROA-20.8%
% insiders2.1%
% institutions62.1%
Last declaration on 22 September 2026
Declarations55 total
5,750 shares0Common StockSEC:0001193125-26-397873:0
2,875 sharesCommon StockSEC:0001296998-26-000002:0
2,875 sharesCommon StockSEC:0001219866-26-000002:0
2,875 sharesCommon StockSEC:0001286338-26-000002:0
2,875 sharesCommon StockSEC:0001237401-26-000002:0
108,695 sharesCommon StockSEC:0001644071-26-000002:0
Canonical exit: 30 Jun 2026 (T+90)
129,833 shares0Common StockSEC:0001178253-26-000004:0
129,833 shares0Common StockSEC:0001193125-26-033583:0
391,333 shares0Common StockSEC:0001178253-26-000003:0
32,500 shares@ US$0.7630.9% of flowCommon StockSEC:0001178253-25-000007:0
23,000 shares0Common StockSEC:0000950170-25-091602:0
23,000 shares0Common StockSEC:0000950170-25-091598:0
23,000 shares0Common StockSEC:0000950170-25-091589:0
23,000 shares0Common StockSEC:0000950170-25-091570:0
23,000 shares0Common stockSEC:0000950170-25-091562:0
23,000 shares0Common StockSEC:0000950170-25-091555:0
23,000 shares@ US$0.8425.8% of flowCommon StockSEC:0000950170-25-052675:0
5,000 shares@ US$1.077.2% of flowCommon StockSEC:0000950170-25-042838:0
92,511 shares0Common StockSEC:0000950170-25-009188:0
92,511 shares0Common StockSEC:0000950170-25-009173:0
262,927 shares0Common StockSEC:0000950170-25-009170:0
20,000 shares@ US$1.3736.2% of flowCommon StockSEC:0000950170-24-106610:0
Canonical exit: 11 Dec 2024 (T+90)
23,000 shares0Common StockSEC:0000950170-24-076239:0
23,000 shares0Common StockSEC:0000950170-24-076227:0
23,000 shares0Common StockSEC:0000950170-24-076203:0
25 of 55 declarations
About Scynexis Inc
SCYNEXIS, Inc. (ticker: SCYX) is a U.S.-listed biotechnology company traded on the NASDAQ market in the United States. The company is positioned as a developer of innovative medicines for difficult-to-treat and drug-resistant infections, with a historical emphasis on antifungal therapy and, more recently, a strategic tilt toward severe rare diseases. SCYNEXIS was formed as a Delaware corporation in 1999 and is headquartered in Jersey City, New Jersey. In its recent filings and corporate communications, the company describes itself as a clinical-stage biotech focused on addressing significant unmet medical needs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001178253/000095017025038044/scyx-20241231.htm?utm_source=openai))
For much of its corporate history, SCYNEXIS has been centered on ibrexafungerp, marketed as BREXAFEMME®, an oral, non-azole antifungal. This product represented an important therapeutic advance in the treatment of certain vaginal yeast infections, and the company has also explored broader anti-infective applications for the molecule. More recently, SCYNEXIS has signaled a broader pipeline strategy beyond its antifungal foundation, highlighting programs such as SCY-247 and SCY-770 in severe rare disease areas. That evolution suggests a company trying to build a more diversified long-term pipeline around proprietary science and niche clinical needs. ([nasdaq.com](https://www.nasdaq.com/press-release/scynexis-announces-u.s.-availability-of-brexafemmer-ibrexafungerp-tablets-the-first?utm_source=openai))
Read moreShow less
From a competitive standpoint, SCYNEXIS remains a small-cap biopharma company and therefore carries the typical profile of this segment: high scientific risk, regulatory uncertainty, dependence on external capital, and meaningful execution risk around development and commercialization. Its differentiation lies in its antifungal know-how, its first-in-class or novel-mechanism positioning in certain indications, and its potential to unlock value through partnerships. The company’s relatively modest employee base also underscores a lean operating model, consistent with a development-stage biotech rather than a fully scaled commercial pharma company. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001178253/000095017025038044/scyx-20241231.htm?utm_source=openai))
Recent developments are especially relevant for investors. In 2025 and 2026, SCYNEXIS reported progress on transferring the BREXAFEMME NDA to GSK in connection with a potential relaunch, while also advancing its internally controlled programs. The company has emphasized SCY-770 and SCY-247 in recent updates, indicating a pipeline reorientation toward rare disease opportunities. On the capital markets side, Nasdaq granted SCYNEXIS a 180-day extension to regain compliance with the minimum bid price requirement, which points to continued share-price pressure. Taken together, these developments make SCYNEXIS a speculative but potentially interesting biotech story, with upside tied primarily to clinical execution, regulatory milestones, and strategic partnering. ([ir.scynexis.com](https://ir.scynexis.com/news-events/press-releases/detail/347/scynexis-reports-second-quarter-2025-financial-resultsand?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
